Sep 11, 2020
Clene Nanomedicine Presents Interim Results from REPAIR-MS and REPAIR-PD Phase 2 Studies
Sep 08, 2020
Clene Nanomedicine, Inc. Completes Enrollment in Rescue-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
Sep 02, 2020
Clene Nanomedicine, Inc. to go Public through Merger with Tottenham Acquisition I Limited
Aug 26, 2020
Clene Nanomedicine Raises Series D Financing of $42.5 Million
Aug 03, 2020
Clene Nanomedicine Announces First Patients Enrolled in HEALEY ALS Platform Trial
Feb 27, 2020
Clene Nanomedicine Presents Blinded Interim Data from the VISIONARY-MS Phase 2 Study
Jan 24, 2020
Clene Nanomedicine Announces Formal Acceptance of CNM-Au8 for HEALEY ALS Platform Trial as Center Receives FDA Approval to Proceed
Jan 21, 2020
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
Jan 09, 2020
Clene Nanomedicine Announces First Patient Dosed in the REPAIR-MS Clinical Trial for the Treatment of Multiple Sclerosis with Lead Nanocatalytic Therapeutic, CNM-Au8
Dec 03, 2019
Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson's Disease with the Nanocatalytic Therapeutic, CNM-Au8
Sep 18, 2019
Clene Nanomedicine, Inc. Announces Selection of CNM-Au8 for the Harvard Led HEALEY ALS Platform Trial, a Clinical Trial for Amyotrophic Lateral Sclerosis
Sep 17, 2019
Clene Nanomedicine, Inc. Awarded $1.37M AUD Grant from FightMND to Conduct Phase 2 Clinical Study for the Treatment of Amyotrophic Lateral Sclerosis
Feb 02, 2018
Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting